Valeant Pharmaceutical (VRX) Reports Q2 Earnings of $0.73; Raises FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Research and development costs, net: 11.95M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Research and development costs, net: 11.95M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q2 EPS of $0.73, versus $0.60 reported last year. Revenue for the quarter came in at $609 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
- KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
